REPORT HIGHLIGHTS

The global market for breast cancer diagnostic and drug technologies was about $20.8 billion in 2012. This market reached about $22.3 billion in 2014 and is expected to reach $27 billion in 2019, registering a compound annual growth rate (CAGR) of 4% through 2014-2019.

This report provides:

An overview of the global market for breast cancer diagnostics and drug technologies.
Analyses of market trends, with data from 2012, estimates for 2014, and projections of CAGRs through 2019.
A comprehensive review of emerging breast cancer personalized and predictive diagnostic tests, particularly with regard to companion tests, tumor markers, and gene profiling assays relevant for breast cancer prognosis and diagnosis.
Information on products in the market and detailed analyses of the market's segments and competitive environments.
Assessments of technological developments, product innovations, and recent strategic industry activity of across different product categories.
Comprehensive company profiles of major players in the industry.

SCOPE AND FORMAT

This report provides an update and overview on predictive testing in breast cancer diagnostics and drug technologies and global markets as well as global incidence rates for breast cancer. The study’s objective is to review tumor marker-based predictive companion tests and drugs for breast cancer, and then assess their global growth potential over a five-year period from 2014 to 2019. The comprehensive review includes global markets for current drugs, new developments, predictive diagnostic tests and new technologies, drugs and developments. The report forecasts market trends forecast trends for the use of current tests for better diagnosis and prognosis of breast cancer through 2019.
Important current diagnostic tests, technologies and developments; market share by drug, test and current products on the market; market share by company or product; and statistical information for types of breast cancer incidence and prevalence globally, with special emphasis on the U.S. market, are discussed. The report focuses on tumor marker-based testing, which provides vital information about the cancer.These tests can help determine the appropriate medicine and timing of treatment to address the disease most effectively. The report also includes information on current issues and trends affecting the industry. The report covers products in development, new technologies, trends, alliances, new developments and patents and mergers. It offers market data with respect to segments and geography. Other breast cancer detection and screening technologies and markets (e.g., mammography, ultrasound, biopsy) are not included in this report

Table Of Contents


Chapter- 1: INTRODUCTION - Complimentary 4

STUDY GOALS AND OBJECTIVES
REASONS FOR COMPLETING THE STUDY
SCOPE AND FORMAT
INTENDED AUDIENCE
METHODOLOGY
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER

Chapter- 2: SUMMARY 3

Table Summary : GLOBAL MARKET FOR BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2019
Figure Summary : GLOBAL MARKET FOR BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2012-2019

Chapter- 3: OVERVIEW 10

INTRODUCTION

Chapter- 4: BREAST CANCER 26

LATEST DEVELOPMENTS
BREAST CANCER DIAGNOSTICS AND TRENDS
FUTURE OF BREAST CANCER DETECTION

Chapter- 5: BIOMARKERS AND DEVELOPMENT OF CANCER DIAGNOSTICS 38

BIOMARKERS AND CANCER
BIOMARKERS AND BREAST CANCER
INCREASED USE OF BIOMARKERS IN DRUG DEVELOPMENT AND CLINICAL TRIALS

Chapter- 6: BREAST CANCER PREVALENCE AND INCIDENCE RATES 54

CANCER INCIDENCE GLOBALLY
BREAST CANCER GLOBALLY
CONCLUSIONS

Chapter- 7: BREAST CANCER DRUGS AND MARKET TRENDS 40

CLINICAL DIAGNOSIS AND MANAGEMENT
CANCER DRUGS AND MARKET TRENDS
GLOBAL PHARMACEUTICAL MARKET
CURRENT BREAST CANCER MARKET TRENDS
BREAST CANCER MARKET
CONCLUSIONS

Chapter- 8: BREAST CANCER PREDICTIVE DIAGNOSTICS MARKET 42

PROJECTED CANCER COSTS
CANCER DRUG MARKET
BREAST CANCER DRUGS
U.S. PERSONALIZED MEDICINE MARKET SIZE
GLOBAL MOLECULAR DIAGNOSTICS MARKET
GLOBAL IN VITRO DIAGNOSTICS MARKET
GLOBAL BREAST CANCER MARKET AND TRENDS
KEY COMPANIES
GENOMIC ASSAYS
CONCLUSIONS

Chapter- 9: COMPANY PROFILES 16

ABBOTT LABORATORIES
AETERNA ZENTARIS
AGENDIA
ALTHEADX
AMBERGEN INC.
ASTRAZENECA PLC
ATOSSA GENETICS INC.
BIOCON
BIOTIME
CCC DIAGNOSTICS LLC
CLARIENT
DAKO
EISAI INC.
EUTROPICS PHARMACEUTICALS
FLUXION BIOSCIENCES
GENENTECH
GENOMIC HEALTH
GLAXOSMITHKLINE
LIFE TECHNOLOGIES CORP.
MATRIX-BIO INC.
MDXHEALTH
MERCK AND CO. INC.
MYRIAD GENETICS
NANOSTRING TECHNOLOGIES
PFIZER
PHIGENIX
PROVISTADX LABORATORIES
PURDUE RESEARCH FOUNDATION
RUBICON GENOMICS
SANOFI S.A.
VENTANA MEDICAL SYSTEMS INC.

Chapter- 10: DEVELOPMENTS AND COLLABORATIONS 20

CURRENT AND FUTURE DEVELOPMENTS
CONCLUSIONS

Chapter- 11: BIBLIOGRAPHY 6

List of Tables

Summary Table : GLOBAL MARKET FOR BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2019
Table 1 : SEER SUMMARY STAGE SYSTEM FOR BREAST CANCER
Table 2 : TYPES OF HORMONE THERAPY FOR BREAST CANCER
Table 3 : BREAST CANCER STAGES
Table 4 : BREAST CANCER GRADES
Table 5 : IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD
Table 6 : TESTS USED TO EVALUATE DIFFERENT GENE SETS FOR BREAST CANCER TREATMENT
Table 7 : BIOPSY AND SURGICAL SAMPLE TESTING TECHNIQUES
Table 8 : HER2 TESTING AND VARIATIONS
Table 9 : GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN
Table 10 : RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER
Table 11 : FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE
Table 12 : APPROVED COMPANION DIAGNOSTICS FOR BREAST CANCER
Table 13 : CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE
Table 14 : CLINICALLY RELEVANT BIOMARKERS
Table 15 : FDA APPROVED CANCER DRUGS, 2014
Table 16 : ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION
Table 17 : BREAST CANCER MDX TECHNOLOGY PLATFORMS
Table 18 : NEXT GENERATION BREAST CANCER TESTS
Table 19 : DIAGNOSED CASES OF CANCER EXCLUDING NON-MELANOMA SKIN CANCER, 2012
Table 20 : MOST COMMONLY DIAGNOSED CANCERS GLOBALLY, 2012
Table 21 : AGE STANDARDIZED CANCER RATE PER 100,000 PEOPLE IN DEVELOPED AND LESS DEVELOPED COUNTRIES, 2012
Table 22 : BREAST CANCER INCIDENCE AND MORTALITY GLOBALLY, 2008
Table 23 : BREAST CANCER INCIDENCE BY COUNTRY, 2012
Table 24 : ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2011-2019
Table 25 : NEW BREAST CANCER CASES BY GEOGRAPHIC REGION, 2009 AND 2012
Table 26 : ESTIMATED GLOBAL BREAST CANCER INCIDENCE RATES FOR ALL AGES, 2012
Table 27 : POTENTIAL REDUCTION IN DEATHS DUE TO BREAST CANCER FROM EARLY DETECTION, U.K. AND U.S.
Table 28 : U.S. ESTIMATED BREAST CANCER INCIDENCE, BY GENDER, 2010-2019
Table 29 : U.S. NEW FEMALE BREAST CANCER CASES AND DEATHS BY AGE, 2011
Table 30 : U.S. ESTIMATED BREAST CANCER INCIDENCE AND DEATHS, 2012
Table 31 : COMPARISON OF BREAST CANCER INCIDENCE AND DEATH IN MEN AND WOMEN IN THE U.S., 2012
Table 32 : U.S. ESTIMATED BREAST CANCER INCIDENCE AND MORTALITY BY RACE, 2006-2010
Table 33 : U.S. ESTIMATED BREAST CANCER INCIDENCE (2004-2008) AND MORTALITY (2003-2007) FOR ASIAN WOMEN
Table 34 : U.S. ESTIMATED BREAST CANCER INCIDENCE AND MORTALITY FOR HISPANIC/LATINA WOMEN, 2006-2010
Table 35 : U.S. ESTIMATED BREAST CANCER INCIDENCE AND MORTALITY IN NATIVE AMERICAN WOMEN COMPARED WITH OTHER RACES, 2006-2010
Table 36 : BREAST CANCER RISK BY AGE
Table 37 : RELATIVE CANCER SURVIVAL IN WOMEN IN THE U.S.
Table 38 : ESTIMATED CANADIAN BREAST CANCER STATISTICS, 2014
Table 39 : CANADIAN ESTIMATED NUMBER OF NEW BREAST CANCER CASES IN FEMALES BY AGE, 2010
Table 40 : ESTIMATED NEW BREAST CANCER CASES, DEATHS FROM CANCER AND AGE-STANDARDIZED RATES PER 100,000 IN EUROPE, 2012
Table 41 : BREAST CANCER STATISTICS IN THE U.K. AND IRELAND
Table 42 : U.K. AGE STANDARDIZED BREAST CANCER INCIDENCE RATES, 2011
Table 43 : U.K. AGE-STANDARDIZED BREAST CANCER INCIDENCE RATES, 2008
Table 44 : ESTIMATED INCIDENCE OF BREAST CANCER IN THE U.K.., 2008-2019
Table 45 : GERMAN ESTIMATED BREAST CANCER INCIDENCE, 2010-2019
Table 46 : PROJECTED NEW CASES OF BREAST CANCER IN AUSTRALIA AND NEW ZEALAND, 2012
Table 47 : ASIAN ESTIMATED BREAST CANCER INCIDENCE, 2012
Table 48 : CHINESE ESTIMATED BREAST CANCER INCIDENCE, 2008-2019
Table 49 : INDIAN ESTIMATED BREAST CANCER INCIDENCE, 2008-2019
Table 50 : JAPANESE ESTIMATED BREAST CANCER INCIDENCE, 2010-2012
Table 51 : FIVE-YEAR SURVIVAL RATES FOR BREAST CANCER
Table 52 : SELECTED BREAST CANCER FIVE-YEAR SURVIVAL BY CANCER STAGE
Table 53 : U.S. PERCENTAGE OF BREAST CANCER CASES AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, 2004-2010
Table 54 : ONCOLOGY DRUGS APPROVED BY THE FDA, 2014
Table 55 : ONCOLOGY DRUGS APPROVED BY THE FDA, 2013
Table 56 : ONCOLOGY DRUGS APPROVED BY THE FDA, 2012
Table 57 : ONCOLOGY DRUGS APPROVED BY THE FDA, 2011
Table 58 : ONCOLOGY DRUGS APPROVED BY THE FDA, 2010
Table 59 : DRUGS APPROVED TO TREAT BREAST CANCER
Table 60 : HORMONE THERAPY FOR BREAST CANCER
Table 61 : AROMATASE INHIBITORS FOR TREATING BREAST CANCER
Table 62 : CHEMOTHERAPY DRUGS FOR TREATING BREAST CANCER
Table 63 : TARGETED THERAPEUTICS FOR BREAST CANCER
Table 64 : GLOBAL MARKET FOR TARGETED CANCER DRUGS, 2008-2019
Table 65 : GLOBAL PHARMACEUTICAL SALES, THROUGH 2019
Table 66 : BREAST CANCER THERAPY SALES, THROUGH 2019
Table 67 : BREAST CANCER DRUG MARKET, 2014 AND 2019
Table 68 : PERJETA DRUG SALES, 2012-2014
Table 69 : KADCYLA DRUG SALES, 2013 AND 2014
Table 70 : HERCEPTIN DRUG SALES, 2012-2014
Table 71 : BREAST CANCER TARGETED THERAPIES, 2010-2014
Table 72 : ROCHE PHARMACEUTICALS DIVISION SALES, 2012-2013
Table 73 : ROCHE SALES COMPARED WITH THE GLOBAL MARKET, 2010
Table 74 : XELODA SALES, 2010 AND 2011
Table 75 : ROCHE SALES VERSUS THE GLOBAL MARKET, 2011
Table 76 : EXPECTED SALES FOR PERTUZUMAB, 2016
Table 77 : AUSTRALIA: CANCER THERAPY SALES, 2008 AND 2018
Table 78 : AUSTRALIA TARGETED CANCER THERAPY SALES, 2008 AND 2018
Table 79 : BREAST CANCER MONOCLONAL ANTIBODY MARKET, 2014 AND 2019
Table 80 : ANNUALIZED MEAN NET COST OF BREAST CANCER CARE, 2010
Table 81 : U.S. PREDICTIVE PERSONALIZED MEDICINE MARKET, 2013 AND 2019
Table 82 : U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, THROUGH 2019
Table 83 : GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2019
Table 84 : GLOBAL IVD MARKET, THROUGH 2019
Table 85 : BREAST CANCER DIAGNOSTIC TESTS
Table 86 : BREAST CANCER GENETIC TESTS
Table 87 : ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2012-2019
Table 88 : GLOBAL INCIDENCE OF ER-POSITIVE BREAST CANCER, 2012-2019
Table 89 : BREAST CANCER DIAGNOSTIC TEST COSTS
Table 90 : GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, THROUGH 2019
Table 91 : IHC AND FISH-BASED BREAST CANCER TESTING SALES, THROUGH 2019
Table 92 : FDA-APPROVED COMMERCIAL IHC KITS
Table 93 : FDA-APPROVED FISH ANALYSIS TESTS
Table 94 : ONCOLOGY BREAST CANCER DRUG SALES BY REGION, 2013
Table 95 : ROCHE DIAGNOSTIC SALES, 2012 AND 2013
Table 96 : ROCHE SALES BY DIVISION, 2010
Table 97 : CURRENTLY MARKETED ROCHE COMPANION DIAGNOSTICS
Table 98 : GENOMIC ASSAY MARKET LEADERS
Table 99 : GENOMIC TESTING MARKET FOR BREAST CANCER, THROUGH 2019
Table 100 : ONCOTYPE DX SALES, THROUGH 2019
Table 101 : QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, THROUGH 2019
Table 102 : BUPARLISIB CLINICAL TRIALS
Table 103 : AFINITOR PATENTS AND EXPIRY

List of Figures

Summary Figure : GLOBAL MARKET FOR BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2012-2019
Figure 1 : GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2008
Figure 2 : ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2011-2019
Figure 3 : U.S. ESTIMATED BREAST CANCER INCIDENCE, BY GENDER, 2010-2019
Figure 4 : ESTIMATED INCIDENCE OF BREAST CANCER IN THE U.K., 2008-2019
Figure 5 : GERMAN ESTIMATED BREAST CANCER INCIDENCE, 2010-2019
Figure 6 : CHINESE ESTIMATED BREAST CANCER INCIDENCE, 2008-2019
Figure 7 : INDIAN ESTIMATED BREAST CANCER INCIDENCE, 2008-(NO. OF CASES)2019
Figure 8 : GLOBAL PHARMACEUTICAL SALES, 2010-2019
Figure 9 : BREAST CANCER THERAPY SALES, 2010-2019
Figure 10 : BREAST CANCER DRUG MARKET, 2014 AND 2019
Figure 11 : U.S. PERSONALIZED MEDICINE MARKET, 2013 AND 2019
Figure 12 : U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, 2011-2019
Figure 13 : GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, 2012-2019
Figure 14 : IHC AND FISH-BASED BREAST CANCER TESTING SALES, 2012-2019
Figure 15 : GENOMIC TESTING MARKET FOR BREAST CANCER, 2012-2019
Figure 16 : QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, 2012-2019

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cance ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

  • $ 7 000
  • Industry report
  • November 2014
  • by Occams

According to WHO approximately 17.3 million people die annually due to CVD and the condition is responsible for 30 percent of the global deaths. Also, 80 percent of CVD deaths take place in low and middle ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.